RVNC News and Press, Revance Therapeutics Inc. From 10/14/19

Revance Therapeutics ( RVNC +2.7% ) appoints Mark Foley as President and CEO, replacing Dan Browne, who resigned due to a misjudgment in handling an employee matter. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Read more ...

- Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of glabellar lines in the Fall of 2019, as previously announce...

Nestle S.A. ( OTCPK:NSRGY ) subsidiary Galderma announces positive results from a Phase 2 clinical trial evaluating QM1114, its ready-to-use liquid formulation of botulinum toxin type A, for the treatment of glabellar lines (frown lines). More news on: Nestlé S.A., Allergan plc, Evo...

Revance Therapeutics ( RVNC ) is a late entrant to the differentiated botulinum toxin market, but its promise lies in a possibly longer duration of response with its drug DaxibotulinumtoxinA for Injection ((DAXI)), which may enable patients to take fewer injections every year, reducing treatme...

The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at Great Place to Work® for the second con...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York, NY. Chief Financial Of...

The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan Stanley 17th Annual Global Healthcare Conference, in New York, NY. Pr...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare Conference, in Boston, MA. President and ...